GLP‑1 weight‑loss drugs offer heart benefits but need lasting lifestyle plan

GLP‑1 medications, including Ozempic, Wegovy and Mounjaro, have seen a surge in use for weight loss and type‑2 diabetes, with surveys indicating roughly one‑in‑five adults in the United States have tried them.

UK GP Dr Adam Staten advises every patient to ask a single “golden” question before starting: “What lifestyle do you want to end up with?” He stresses that the injections are only a tool and that long‑term habit changes—enjoyable exercise, higher‑quality nutrition and protein intake—are essential to keep weight off once treatment stops.

Cardiovascular research cited by a Dutch cardiologist shows a roughly 20 % reduction in serious heart‑ and vascular events among overweight patients using semaglutide, linking the benefit to loss of abdominal fat.

Separate studies report that semaglutide may lower impulsive and violent behaviours and an early trial in people living with HIV suggested a slowdown in biological aging markers, prompting speculation about longevity effects.

Experts also note common side‑effects such as nausea, vomiting and potential muscle loss, and warn that the high cost of ongoing low‑dose therapy may be prohibitive for many. Sustainable outcomes, they say, require a comprehensive lifestyle plan alongside the medication.